Global Suppression of IL-6-induced Acute Phase Response Gene Expression after Chronic in Vivo Treatment with the Peroxisome Proliferator-activated Receptor-α Activator Fenofibrate

Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism

Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,115

Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway

HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130

Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?

Yudkin, J. S., Kumari, M., Humphries, S. E., & Mohamed-Ali, V. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00463-3 · Cited by 1,775

gp 130 AND THE INTERLEUKIN-6 FAMILY OF CYTOKINES

Taga, T., & Kishimoto, T. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.797 · Cited by 1,468

Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels

Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F. M., Moye, L. A., Goldman, S., Flaker, G. C., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.9.839 · Cited by 1,389

The PPARα–leukotriene B4 pathway to inflammation control

Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W. (1996) · Nature · doi:10.1038/384039a0 · Cited by 1,345

Novel Risk Factors for Systemic Atherosclerosis

Ridker, P. M., Stampfer, M. J., & Rifai, N. (2001) · JAMA · doi:10.1001/jama.285.19.2481 · Cited by 1,290

Tissue-specific in vitro transcription from the mouse albumin promoter

Gorski, K., Carneiro, M., & Schibler, U. (1986) · Cell · doi:10.1016/0092-8674(86)90519-2 · Cited by 1,227

Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators

Staels, B., Köenig, W., Habib, A., Merval, R., Lebret, M., Pineda‐Torra, I., Delerive, P., Fadel, A., Chinetti, G., Fruchart, J., et al. (1998) · Nature · doi:10.1038/31701 · Cited by 1,138

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089

Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease

Pawlak, M., Lefebvre, P., & Staels, B. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.039 · Cited by 1,578

Peroxisome Proliferator-Activated Receptor Alpha Target Genes

Rakhshandehroo, M., Knoch, B., Müller, M., & Kersten, S. (2010) · PPAR Research · doi:10.1155/2010/612089 · Cited by 1,020

Sorting out the roles of PPAR in energy metabolism and vascular homeostasis

Lefebvre, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27989 · Cited by 962

Ppars are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation

Varga, T., Czimmerer, Z., & Nagy, L. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.02.014 · Cited by 933

Molecular Actions of PPARα in Lipid Metabolism and Inflammation

Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00064 · Cited by 898

PPARs and molecular mechanisms of transrepression

Ricote, M., & Glass, C. K. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.013 · Cited by 580

Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms

Straus, D. S., & Glass, C. K. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.09.003 · Cited by 563

Suppression of hepcidin during anemia requires erythropoietic activity

Pak, M., Lopez, M. A., Gabayan, V., Ganz, T., & Rivera, S. (2006) · Blood · doi:10.1182/blood-2006-06-028787 · Cited by 472

The role and regulation of the peroxisome proliferator activated receptor alpha in human liver

Kersten, S., & Stienstra, R. (2017) · Biochimie · doi:10.1016/j.biochi.2016.12.019 · Cited by 405

Molecular pathways in non-alcoholic fatty liver disease

Auguet, T., Berlanga, A., Guiu‐Jurado, E., & Porras, J. A. (2014) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s62831 · Cited by 395

Nutrition-induced ketosis alters metabolic and signaling gene networks in liver of periparturient dairy cows

Loor, J. J., Everts, R. E., Bionaz, M., Dann, H. M., Morin, D. E., Oliveira, R., Rodriguez‐Zas, S. L., Drackley, J. K., & Lewin, H. A. (2007) · Physiological Genomics · doi:10.1152/physiolgenomics.00188.2007 · Cited by 373

Evaluation of C-Reactive Protein Measurement for Assessing the Risk and Prognosis in Ischemic Stroke

Napoli, M. D., Schwaninger, M., Cappelli, R., Ceccarelli, E., Gianfilippo, G. D., Donati, C., Emsley, H. C. A., Forconi, S., Hopkins, S. J., Masotti, L., et al. (2005) · Stroke · doi:10.1161/01.str.0000165929.78756.ed · Cited by 290

PPARs, Obesity, and Inflammation

Stienstra, R., Duval, C., Müller, M., & Kersten, S. (2007) · PPAR Research · doi:10.1155/2007/95974 · Cited by 287

Roles of PPARs in NAFLD: Potential therapeutic targets

Tailleux, A., Wouters, K., & Staels, B. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.016 · Cited by 289

Nuclear receptors and nonalcoholic fatty liver disease

Cave, M. C., Clair, H. B., Hardesty, J., Falkner, K. C., Feng, W., Clark, B. J., Sidey, J., Shi, H., Aqel, B. A., McClain, C. J., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.03.002 · Cited by 292

Mitochondrial Quality Control as a Therapeutic Target

Suliman, H. B., & Piantadosi, C. A. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.011502 · Cited by 267

Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque

Janoudi, A., Shamoun, F. E., Kalavakunta, J. K., & Abela, G. S. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv653 · Cited by 243

The G0/G1 switch gene 2 is a novel PPAR target gene.

Zandbergen, F., Mandard, S., Escher, P., Tan, N., Patsouris, D., Jatkoe, T., Rojas-Caro, S., Madore, S., Wahli, W., Tafuri, S., et al. (2005) · Biochemical Journal · doi:10.1042/bj20050636 · Cited by 235

Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk

Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227

Comprehensive Analysis of PPARα-Dependent Regulation of Hepatic Lipid Metabolism by Expression Profiling

Rakhshandehroo, M., Sanderson, L. M., Matilainen, M., Stienstra, R., Carlberg, C., de Groot, P. J., Müller, M., & Kersten, S. (2007) · PPAR Research · doi:10.1155/2007/26839 · Cited by 241

PPARα in atherosclerosis and inflammation

Zandbergen, F. J., & Plutzky, J. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.021 · Cited by 219

Peroxisome Proliferator-Activated Receptor α Protects against Obesity-Induced Hepatic Inflammation

Stienstra, R., Mandard, S., Patsouris, D., Maass, C., Kersten, S., & Müller, M. M. (2007) · Endocrinology · doi:10.1210/en.2007-0014 · Cited by 196

Protective Effects of (E)-β-Caryophyllene (BCP) in Chronic Inflammation

Scandiffio, R., Geddo, F., Cottone, E., Querio, G., Antoniotti, S., Gallo, M. P., Maffei, M. E., & Bovolin, P. (2020) · Nutrients · doi:10.3390/nu12113273 · Cited by 194

Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR–α Activators

Zambon, A., Gervois, P. P., Pauletto, P., Fruchart, J., & Staels, B. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000204327.96431.9a · Cited by 162

Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors

Gervois, P. P., Fruchart, J., & Staels, B. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0397 · Cited by 159

The Role of PPAR α Activation in Liver and Muscle

Burri, L., Thoresen, G. H., & Berge, R. K. (2010) · PPAR Research · doi:10.1155/2010/542359 · Cited by 173

PPARα ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-κB and AP-1 pathways

Ramanan, S., Kooshki, M., Zhao, W., Hsu, F., & Robbins, M. E. C. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.09.002 · Cited by 162

PPARα inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a

Gizard, F., Amant, C., Barbier, O., Bellosta, S., Robillard, R., Percevault, F., Sevestre, H., Krimpenfort, P., Corsini, A., Rochette, J., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci22756 · Cited by 167

Time-Resolved and Tissue-Specific Systems Analysis of the Pathogenesis of Insulin Resistance

Kleemann, R., van Erk, M., Verschuren, L., van den Hoek, A. M., Koek, M., Wielinga, P. Y., Jie, A., Pellis, L., Bobeldijk-Pastorova, I., Kelder, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008817 · Cited by 146

The connection between C‐reactive protein and atherosclerosis

Singh, S. K., Suresh, M. V., Voleti, B., & Agrawal, A. C. (2008) · Annals of Medicine · doi:10.1080/07853890701749225 · Cited by 145

Major urinary protein-1 increases energy expenditure and improves glucose intolerance through enhancing mitochondrial function in skeletal muscle of diabetic mice

Hui, X., Zhu, W., Wang, Y., Lam, K. S. L., Zhang, J., Wu, D., Kraegen, E. W., Li, Y., & Xu, A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.001107 · Cited by 130

Inflammation in Diabetes Mellitus: Role of Peroxisome Proliferator-Activated Receptor–α and Peroxisome Proliferator-Activated Receptor–γ Agonists

Libby, P., & Plutzky, J. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.004 · Cited by 128

Cardiac-Specific Overexpression of Peroxisome Proliferator–Activated Receptor-α Causes Insulin Resistance in Heart and Liver

Park, S., Cho, Y.-R., Finck, B. N., Kim, H.-J., Higashimori, T., Hong, E., Lee, M., Danton, C., Deshmukh, S. D., Cline, G. W., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.9.2514 · Cited by 122

Enhanced expression and activation of pro-inflammatory transcription factors distinguish aneurysmal from atherosclerotic aorta: IL-6- and IL-8-dominated inflammatory responses prevail in the human aneurysm

Lindeman, J. H. N., Abdul-Hussien, H., Schaapherder, A. F., van Bockel, J. H., von der Thüsen, J. H., Roelen, D. L., & Kleemann, R. (2008) · Clinical Science · doi:10.1042/cs20070352 · Cited by 118

Treating NASH by targeting peroxisome proliferator-activated receptors

Staels, B., Butruille, L., & Francque, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.004 · Cited by 114

Sodium Butyrate Ameliorates High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease through Peroxisome Proliferator-Activated Receptor α-Mediated Activation of β Oxidation and Suppression of Inflammation

Sun, B., Jia, Y., Hong, J., Sun, Q., Gao, S., Hu, Y., Zhao, N., & Zhao, R. (2018) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b01189 · Cited by 108

Gene expression profiling in the lung and liver of PFOA-exposed mouse fetuses

Rosen, M. B., Thibodeaux, J. R., Wood, C. R., ZEHR, R. D. J., Schmid, J. E., & Lau, C. S. (2007) · Toxicology · doi:10.1016/j.tox.2007.06.095 · Cited by 108

Evaluation of chronic toxicity and carcinogenicity of ammonium 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)-propanoate in Sprague–Dawley rats

Caverly Rae, J. M., Craig, L., Slone, T. W., Frame, S. R., Buxton, L. W., & Kennedy, G. L. (2015) · Toxicology Reports · doi:10.1016/j.toxrep.2015.06.001 · Cited by 102

DAP12 (KARAP) amplifies inflammation and increases mortality from endotoxemia and septic peritonitis

Turnbull, I. R., McDunn, J. E., Takai, T., Townsend, R. R., Cobb, J. P., & Colonna, M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050986 · Cited by 99

Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia

Jha, P., Claudel, T., Baghdasaryan, A., Mueller, M., Halilbasic, E., Das, S. K., Lass, A., Zimmermann, R., Zechner, R., Höefler, G., et al. (2013) · Hepatology · doi:10.1002/hep.26732 · Cited by 97

Fenofibrate, a peroxisome proliferator-activated receptor α agonist, exerts neuroprotective effects in traumatic brain injury

Besson, V. C., Chen, X. R., Plotkine, M., & Marchand‐Leroux, C. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.06.019 · Cited by 98

Key points for the development of antioxidant cocktails to prevent cellular stress and damage caused by reactive oxygen species (ROS) during manned space missions

Gómez, X., Sanon, S., Zambrano, K., Asquel, S., Bassantes, M., Morales, J. E., Otáñez, G., Pomaquero, C., Villarroel, S., Zurita, A., et al. (2021) · npj Microgravity · doi:10.1038/s41526-021-00162-8 · Cited by 92

In utero and lactational exposure to BDE-47 promotes obesity development in mouse offspring fed a high-fat diet: impaired lipid metabolism and intestinal dysbiosis

Wang, D., Yan, J., Teng, M., Yan, S., Zhou, Z., & Zhu, W. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2177-0 · Cited by 88

PPARα activators upregulate eNOS activity and inhibit cytokine-induced NF-κB activation through AMP-activated protein kinase activation

Okayasu, T., Tomizawa, A., Suzuki, K., Manaka, K., & Hattori, Y. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.02.002 · Cited by 93

Multi-omics analysis of multiple missions to space reveal a theme of lipid dysregulation in mouse liver

Beheshti, A., Chakravarty, K., Fogle, H., Fazelinia, H., Silveira, W. A. D., Boyko, V., Polo, S.-H. L., Saravia-Butler, A. M., Hardiman, G., Taylor, D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55869-2 · Cited by 90

Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia

Undas, A., Celińska‐Löwenhoff, M., Domagała, T. B., Iwaniec, T., Dropiński, J., Löwenhoff, T., & Szczeklik, A. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-01-0067 · Cited by 90

Acyl-CoA Thioesterase 1 (ACOT1) Regulates PPARα to Couple Fatty Acid Flux With Oxidative Capacity During Fasting

Franklin, M. P., Sathyanarayan, A., & Mashek, D. G. (2017) · Diabetes · doi:10.2337/db16-1519 · Cited by 87

The impact of PPARα activation on whole genome gene expression in human precision cut liver slices

Janssen, A. W. F., Betzel, B., Stoopen, G. M., Berends, F. J., Janssen, I. M. C., Peijnenburg, A., & Kersten, S. (2015) · BMC Genomics · doi:10.1186/s12864-015-1969-3 · Cited by 85

Nuclear Control of the Inflammatory Response in Mammals by Peroxisome Proliferator-Activated Receptors

Mandard, S., & Patsouris, D. (2013) · PPAR Research · doi:10.1155/2013/613864 · Cited by 84

Transgenic Flavonoid Tomato Intake Reduces C-Reactive Protein in Human C-Reactive Protein Transgenic Mice More Than Wild-Type Tomato

Rein, D., Schijlen, E. G. W. M., Kooistra, T., Herbers, K., Verschuren, L., Hall, R. D., Sonnewald, U., Bovy, A. G., & Kleemann, R. (2006) · Journal of Nutrition · doi:10.1093/jn/136.9.2331 · Cited by 82

Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis

Bazwinsky‐Wutschke, I., Zipprich, A., & Dehghani, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102516 · Cited by 85

Fenofibrate Reduces Atherogenesis in ApoE*3Leiden Mice

Kooistra, T., Verschuren, L., der Weij, J. D. V.-V., Köenig, W., Toet, K. H., Princen, H. M. G., & Kleemann, R. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000238348.05028.14 · Cited by 80

Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors

Mandard, S., Stienstra, R., Escher, P., Tan, N. S., Kim, I., Gonzalez, F. J., Wahli, W., Desvergne, B., Müller, M. M., & Kersten, S. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7006-1 · Cited by 80

Immune-regulation of the apolipoprotein A-I/C-III/A-IV gene cluster in experimental inflammation

Navarro, M. Á., Carpintero, R., Acı́n, S., Arbonés-Mainar, J. M., Calleja, L., Carnicer, R., Surra, J. C., Guzmán-García, M. A., González‐Ramón, N., Iturralde, M., et al. (2005) · Cytokine · doi:10.1016/j.cyto.2005.03.002 · Cited by 79

The Interleukin-1 receptor antagonist is a direct target gene of PPARα in liver

Stienstra, R., Mandard, S., Tan, N. S., Wahli, W., Trautwein, C., Richardson, T. A., Lichtenauer-Kaligis, E. G. R., Kersten, S., & Müller, M. M. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2006.11.019 · Cited by 80

Serum levels of perfluoroalkyl acids (PFAAs) with isomer analysis and their associations with medical parameters in Chinese pregnant women

Jiang, W., Zhang, Y., Zhu, L. Y., & Deng, J. (2013) · Environment International · doi:10.1016/j.envint.2013.12.001 · Cited by 75

Nervonic acid and its sphingolipids: Biological functions and potential food applications

Phung, N. V., Rong, F., Xia, W.-Y., Fan, Y., Li, X. Y., Wang, S. A., & Li, F. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2203753 · Cited by 81

Chronic dietary toxicity and carcinogenicity study with ammonium perfluorooctanoate in Sprague–Dawley rats

Butenhoff, J. L., Kennedy, G. L., Chang, S., & Olsen, G. W. (2012) · Toxicology · doi:10.1016/j.tox.2012.04.001 · Cited by 72

Inflammation, thrombosis and acute coronary syndromes

Carter, A. M. (2005) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2005.018 · Cited by 70

Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis

Han, X., Wu, Y., Yang, Q., & Cao, G. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107791 · Cited by 71

Modulation of Airway Remodeling and Airway Inflammation by Peroxisome Proliferator-Activated Receptor γ in a Murine Model of Toluene Diisocyanate-Induced Asthma

Lee, K. S., Park, S. J., Kim, S. R., Min, K. H., Jin, S. M., Lee, H. K., & Lee, Y. C. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.8.5248 · Cited by 71

Systemic and Distal Repercussions of Liver-Specific Peroxisome Proliferator-Activated Receptor-α Control of the Acute-Phase Response

Mansouri, R. M., Baugé, E., Staels, B., & Gervois, P. P. (2008) · Endocrinology · doi:10.1210/en.2007-1339 · Cited by 63

CXCL9 and CXCL11 Chemokines Modulation by Peroxisome Proliferator-Activated Receptor-α Agonists Secretion in Graves’ and Normal Thyrocytes

Antonelli, A., Ferrari, S. M., Frascerra, S., Pupilli, C., Mancusi, C., Metelli, M. R., Orlando, C., Ferrannini, E., & Fallahi, P. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0923 · Cited by 61

Insights into the Role of PPARβ/δ in NAFLD

Chen, J., Montagner, A., Tan, N. S., & Wahli, W. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071893 · Cited by 61

Hypoalbuminemia Predicts Acute Stroke Mortality: Paul Coverdell Georgia Stroke Registry

Famakin, B. M., Weiss, P., Hertzberg, V., McClellan, W., Presley, R. J., Krompf, K., Karp, H. R., & Frankel, M. (2009) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2009.01.015 · Cited by 59

Anti-inflammatory role of fenofibrate in treating diseases

Jin, L., Hu, H., Ji, Y., Jia, Z., Peng, M., & Huang, S. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2022.8534 · Cited by 58

Fenofibrate: a novel formulation (Triglide?) in the treatment of lipid disorders: a review

Τζιόμαλος, Κ., & Athyros, V. G. (2006) · International Journal of Nanomedicine · doi:10.2147/nano.2006.1.2.129 · Cited by 58

Lipids as targets for novel anti-inflammatory therapies

Huwiler, A., & Pfeilschifter, J. M. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.008 · Cited by 60

Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol

Ghonem, N. S., Auclair, A. M., Hemme, C. L., Gallucci, G. M., de la Rosa Rodriguez, R., Boyer, J. L., & Assis, D. N. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1930 · Cited by 57

PPARα as a therapeutic target in inflammation-associated diseases

Gervois, P. P., & Mansouri, R. M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.715633 · Cited by 54

Unraveling the Complex Relationship Triad between Lipids, Obesity, and Inflammation

Khan, S. A., Ali, A., Khan, S. A., Zahran, S. A., Damanhouri, G. A., Azhar, E. I., & Qadri, I. (2014) · Mediators of Inflammation · doi:10.1155/2014/502749 · Cited by 55

Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization

Huang, L., Liang, W., Zhou, K., Wassel, R. A., Ridge, Z., Ma, J., & Wang, B. (2021) · Biology · doi:10.3390/biology10121328 · Cited by 52

Peroxisome proliferator-activated receptors—from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease

Bouhlel, M. A., Staels, B., & Chinetti‐Gbaguidi, G. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01892.x · Cited by 51

PPARs and their Effects on the Cardiovascular System

Oyekan, A. (2011) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2010.531845 · Cited by 52

Up-Regulation and Coexpression of MIF and Matrix Metalloproteinases in Human Abdominal Aortic Aneurysms

Verschuren, L., Lindeman, J. H. N., van Bockel, J. H., Abdul-Hussien, H., Kooistra, T., & Kleemann, R. (2005) · Antioxidants and Redox Signaling · doi:10.1089/ars.2005.7.1195 · Cited by 48

Vesicular Stomatitis Virus Expressing Tumor Suppressor p53 Is a Highly Attenuated, Potent Oncolytic Agent

Heiber, J. F., & Barber, G. N. (2011) · Journal of Virology · doi:10.1128/jvi.05408-11 · Cited by 48

Interleukin-6 Is Essential for Primary Resistance to Francisella tularensis Live Vaccine Strain Infection

Kurtz, S., Foreman, O., Bosio, C., Anver, M., & Elkins, K. (2012) · Infection and Immunity · doi:10.1128/iai.01249-12 · Cited by 45

Pleiotropic effects of fibrates

Chinetti, G., Fruchart, J., & Staels, B. (2005) · Current Atherosclerosis Reports · doi:10.1007/s11883-005-0053-x · Cited by 46

A Dietary Mixture Containing Fish Oil, Resveratrol, Lycopene, Catechins, and Vitamins E and C Reduces Atherosclerosis in Transgenic Mice1–3

Verschuren, L., Wielinga, P. Y., van Duyvenvoorde, W., Tijani, S., Toet, K. H., van Ommen, B., Kooistra, T., & Kleemann, R. (2011) · Journal of Nutrition · doi:10.3945/jn.110.133751 · Cited by 44

Liraglutide Alleviates Hepatic Steatosis and Liver Injury in T2MD Rats via a GLP-1R Dependent AMPK Pathway

Zhou, R., Lin, C., Cheng, Y., Zhuo, X., Li, Q., Xu, W., Zhao, L., & Yang, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.600175 · Cited by 43

Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis

Rahman, S. M., Qadri, I., Janssen, R. C., & Friedman, J. E. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m800633-jlr200 · Cited by 43

Fibrates upregulate TRB3 in lymphocytes independent of PPARα by augmenting CCAAT/enhancer-binding proteinβ (C/EBPβ) expression

Selim, E., Frkanec, J. T., & Cunard, R. A. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2006.06.006 · Cited by 44

Neutrophils as one of the major haptoglobin sources in mastitis affected milk

Lai, I.-H., Tsao, J. H., Lu, Y., Lee, J. W., Zhao, X., Chien, F. L., & Mao, S. J. T. (2008) · Veterinary Research · doi:10.1051/vetres:2008055 · Cited by 44

Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist

Voleti, B., & Agrawal, A. C. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2005.06.045 · Cited by 43

Inflammation, dyslipidaemia, diabetes and PPARs: pharmacological interest of dual PPARα and PPARγ agonists

Gervois, P. P., Fruchart, J., & Staels, B. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-504x.2004.00376.x · Cited by 42

Hepatic gene expression changes in pigs experimentally infected with the lung pathogen Actinobacillus pleuropneumoniae as analysed with an innate immunity focused microarray

Skovgaard, K., Mortensen, S., Boyé, M., Hedegaard, J., & Heegaard, P. M. H. (2009) · Innate Immunity · doi:10.1177/1753425909342730 · Cited by 39

Feasibility and Clinical Significance of In Vivo Cholesterol Crystal Detection Using Optical Coherence Tomography

Katayama, Y., Tanaka, A., Taruya, A., Kashiwagi, M., Nishiguchi, T., Ozaki, Y., Matsuo, Y., Kitabata, H., Kubo, T., Shimada, E., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312934 · Cited by 39

PPARα Ligands Reduce PCB-Induced Endothelial Activation: Possible Interactions in Inflammation and Atherosclerosis

Arzuaga, X., Reiterer, G., Májková, Z., Kilgore, M., Toborek, M., & Hennig, B. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-9005-8 · Cited by 31

A Comparative Perspective on Wnt/β-Catenin Signalling in Cell Fate Determination

Garcin, C. L., & Habib, S. J. (2017) · Results and problems in cell differentiation · doi:10.1007/978-3-319-53150-2_15 · Cited by 40

Alterations of anti-inflammatory lipids in plasma from women with chronic widespread pain - a case control study

Stensson, N., Ghafouri, B., Gerdle, B. U. C., & Ghafouri, N. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0505-7 · Cited by 35

The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD)

Wang, Z., Li, S., Wang, R., Guo, L., Xu, D., Zhang, T., Xu, Y., Wang, W., Wang, M., Gan, Z., et al. (2020) · Molecular Medicine · doi:10.1186/s10020-020-00164-4 · Cited by 34

Mitochondrial-related proteomic changes during obesity and fasting in mice are greater in the liver than skeletal muscles

Nesteruk, M., Hennig, E. E., Mikuła, M., Karczmarski, J., Dzwonek, A., Goryca, K., Rubel, T., Paziewska, A., Woszczyński, M., Ledwon, J. K., et al. (2013) · Functional & Integrative Genomics · doi:10.1007/s10142-013-0342-3 · Cited by 32

Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver Disease

Wang, N., Kong, R., Luo, H., Xu, X., & Lu, J. (2017) · PPAR Research · doi:10.1155/2017/6561701 · Cited by 33

Immunometabolic cross-talk in the inflamed heart

Marelli‐Berg, F. M., & Aksentijević, D. (2019) · Cell Stress · doi:10.15698/cst2019.08.194 · Cited by 36

Regulation of Sexually Dimorphic Expression of Major Urinary Proteins

Penn, D. J., Zala, S. M., & Luzynski, K. C. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.822073 · Cited by 36

The Role of Cannabidiol in Liver Disease: A Systemic Review

Chen, S., & Kim, J.-K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042370 · Cited by 36

Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia

Otto, C., Otto, B., Frost, R. J., Vogeser, M., Pfeiffer, A. F. H., Spranger, J., & Parhofer, K. G. (2007) · Acta Diabetologica · doi:10.1007/s00592-007-0244-8 · Cited by 32

Oleoylethanolamide facilitates PPARα and TFEB signaling and attenuates Aβ pathology in a mouse model of Alzheimer’s disease

Comerota, M. M., Gedam, M., Xiong, W., Jin, F., Deng, L., Wang, M. C., Wang, J., & Zheng, H. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00648-x · Cited by 31

Influence of Genistein on Hepatic Lipid Metabolism in an In Vitro Model of Hepatic Steatosis

Seidemann, L., Krüger, A., Kegel, V., Seehofer, D., & Damm, G. (2021) · Molecules · doi:10.3390/molecules26041156 · Cited by 30

Anti‐Inflammatory and PPAR Transactivational Properties of Flavonoids from the Roots of Sophora flavescens

Quang, T. H., Ngân, N. T. T., Minh, C. V., Kiệm, P. V., Tài, B. H., Nhiệm, N. X., Thảo, N. P., Luyen, B. T. T., Yang, S. Y., & Kim, Y. H. (2012) · Phytotherapy Research · doi:10.1002/ptr.4871 · Cited by 29

Systemic and Distal Repercussions of Liver-Specific Peroxisome Proliferator-Activated Receptor-α Control of the Acute-Phase Response

Mansouri, R. M., Baugé, E., Staels, B., & Gervois, P. P. (2008) · Endocrinology · doi:10.1210/en.2007-1339 · Cited by 63

Fenofibrate, a peroxisome proliferator-activated receptor α-agonist, blocks lipopolysaccharide-induced inflammatory pathways in mouse liver

Won, T. W. (2013) · Korean Journal of Hepato-Biliary-Pancreatic Surgery · doi:10.14701/kjhbps.2013.17.3.89 · Cited by 18

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089

Negative Regulation of Human Fibrinogen Gene Expression by Peroxisome Proliferator-activated Receptor α Agonists via Inhibition of CCAAT Box/Enhancer-binding Protein β

Gervois, P. P., Vu‐Dac, N., Kleemann, R., Kockx, M., Dubois, G., Laine, B., Kosykh, V., Fruchart, J., Kooistra, T., & Staels, B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102839200 · Cited by 159

Interleukin-6 inhibition of peroxisome proliferator-activated receptor alpha expression is mediated by JAK2- and PI3K-induced STAT1/3 in HepG2 hepatocyte cells

Chew, G.-S., Myers, S., Shu‐Chien, A. C., & Muhammad, T. S. T. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1896-z · Cited by 22